NanoViricides closed at $1.38 on Nov 4, down 3.50%, 32.0% below its 52-week closing high. Volume of 89.3K shares was 0.46× its 20-day average (below normal).
Split-adjusted performance: -1.4% over one month, -5.5% over six months, -32.0% over one year.
Short interest was 1.1M shares at the Oct 15 settlement, up 23.4% from the prior report (4.6% of float, 4.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | |
| BTMDBiote | $1.23 | +9.82% | −44.1% | −9.5% | −14.8% | 6.0 | $35.3M | Compare |
| IBOImpact BioMedical | $4.10 | +1.99% | −48.8% | −57.1% | −23300.0% | 44.4 | $35.0M | Compare |
| VERUVeru | $2.20 | +1.85% | −0.9% | — | — | — | $37.5M | Compare |
| LITSLite Strategy | $1.08 | +3.85% | −9.2% | — | — | — | $32.8M | Compare |
| GRCEGrace Therapeutics | $1.81 | −1.63% | −23.6% | — | — | — | $38.1M | Compare |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
| RMTIRockwell Medical, Inc. (DE) | $8.05 | −0.49% | −0.6% | +10.6% | −7.5% | — | $32.4M | Compare |
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | Compare |
No recent articles focused on NanoViricides.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology